APA (7th ed.) Citation

Cortés, J. E., Khaled, S., Martinelli, G., Perl, A. E., Ganguly, S., Russell, N., . . . Levis, M. J. (2019). Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial. The lancet. Oncology, 20(7), . https://doi.org/10.1016/S1470-2045(19)30150-0

Chicago Style (17th ed.) Citation

Cortés, Jorge Eduardo, et al. "Quizartinib Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia (QuANTUM-R): A Multicentre, Randomised, Controlled, Open-label, Phase 3 Trial." The Lancet. Oncology 20, no. 7 (2019). https://doi.org/10.1016/S1470-2045(19)30150-0.

MLA (9th ed.) Citation

Cortés, Jorge Eduardo, et al. "Quizartinib Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia (QuANTUM-R): A Multicentre, Randomised, Controlled, Open-label, Phase 3 Trial." The Lancet. Oncology, vol. 20, no. 7, 2019, https://doi.org/10.1016/S1470-2045(19)30150-0.